119 related articles for article (PubMed ID: 22451198)
1. Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.
Steinman L; Zamvil SS
Ann Neurol; 2012 Mar; 71(3):287-8. PubMed ID: 22451198
[No Abstract] [Full Text] [Related]
2. Aquaporin-Targeted Therapeutics: State-of-the-Field.
Tradtrantip L; Jin BJ; Yao X; Anderson MO; Verkman AS
Adv Exp Med Biol; 2017; 969():239-250. PubMed ID: 28258578
[TBL] [Abstract][Full Text] [Related]
3. Intractable vomiting as the initial presentation of neuromyelitis optica.
Apiwattanakul M; Popescu BF; Matiello M; Weinshenker BG; Lucchinetti CF; Lennon VA; McKeon A; Carpenter AF; Miller GM; Pittock SJ
Ann Neurol; 2010 Nov; 68(5):757-61. PubMed ID: 21031587
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
Lin J; Xue B; Li X; Xia J
Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606
[TBL] [Abstract][Full Text] [Related]
5. The role of AQP4 in neuromyelitis optica: More answers, more questions.
Yang X; Ransom BR; Ma JF
J Neuroimmunol; 2016 Sep; 298():63-70. PubMed ID: 27609277
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled anti-aquaporin-4 protein antibody imaging: a valuable method for determining neuromyelitis optica.
Nemati R; Mehdizadeh S; Nabipour I; Amini A; Assadi M
Nucl Med Commun; 2013 May; 34(5):413-6. PubMed ID: 23535849
[No Abstract] [Full Text] [Related]
7. Gaze palsy, hypogeusia and a probable association with miscarriage of pregnancy--the expanding clinical spectrum of non-opticospinal neuromyelitis optica spectrum disorders: a case report.
Chang T; Withana M
BMC Res Notes; 2015 Feb; 8():36. PubMed ID: 25888897
[TBL] [Abstract][Full Text] [Related]
8. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
[TBL] [Abstract][Full Text] [Related]
9. Individualized rituximab treatment for neuromyelitis Optica spectrum disorders.
McKeon A; Pittock S
JAMA Neurol; 2013 Sep; 70(9):1103-4. PubMed ID: 23896992
[No Abstract] [Full Text] [Related]
10. Isotetrandrine Reduces Astrocyte Cytotoxicity in Neuromyelitis Optica by Blocking the Binding of NMO-IgG to Aquaporin 4.
Sun M; Wang J; Zhou Y; Wang Z; Jiang Y; Li M
Neuroimmunomodulation; 2016; 23(2):98-108. PubMed ID: 27064690
[TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica.
Matiello M; Jacob A; Wingerchuk DM; Weinshenker BG
Curr Opin Neurol; 2007 Jun; 20(3):255-60. PubMed ID: 17495617
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
Jarius S; Paul F; Franciotta D; Waters P; Zipp F; Hohlfeld R; Vincent A; Wildemann B
Nat Clin Pract Neurol; 2008 Apr; 4(4):202-14. PubMed ID: 18334978
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity.
Saini H; Fernandez G; Kerr D; Levy M
J Neuroimmunol; 2010 Apr; 221(1-2):68-72. PubMed ID: 20227773
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.
Hinson SR; Pittock SJ; Lucchinetti CF; Roemer SF; Fryer JP; Kryzer TJ; Lennon VA
Neurology; 2007 Dec; 69(24):2221-31. PubMed ID: 17928579
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
[TBL] [Abstract][Full Text] [Related]
16. Hope for a rare disease: eculizumab in neuromyelitis optica.
Paul F
Lancet Neurol; 2013 Jun; 12(6):529-31. PubMed ID: 23623398
[No Abstract] [Full Text] [Related]
17. Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4.
Miyazaki K; Abe Y; Iwanari H; Suzuki Y; Kikuchi T; Ito T; Kato J; Kusano-Arai O; Takahashi T; Nishiyama S; Ikeshima-Kataoka H; Tsuji S; Arimitsu T; Kato Y; Sakihama T; Toyama Y; Fujihara K; Hamakubo T; Yasui M
J Neuroimmunol; 2013 Jul; 260(1-2):107-16. PubMed ID: 23746426
[TBL] [Abstract][Full Text] [Related]
18. Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes.
Wang Z; Guo W; Liu Y; Gong Y; Ding X; Shi K; Thome R; Zhang GX; Shi FD; Yan Y
Brain Behav Immun; 2017 Oct; 65():173-182. PubMed ID: 28476558
[TBL] [Abstract][Full Text] [Related]
19. Severe aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder with short myelitis lesion and favourable outcome.
Masi G; Cioni C; Arrigucci U; Cerase A; Annunziata P
Neurol Sci; 2015 Oct; 36(10):1925-7. PubMed ID: 26050233
[No Abstract] [Full Text] [Related]
20. Gamma-aminobutyric acid receptor agonists, aquaporin-4, and neuromyelitis optica: a potential link.
Jarius S; Aktas O; Wildemann B
Med Hypotheses; 2015 Nov; 85(5):628-30. PubMed ID: 26323247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
